Baird Financial Group Inc. Has $8.19 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

Baird Financial Group Inc. lowered its position in Glaukos Co. (NYSE:GKOS - Free Report) by 27.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,591 shares of the medical instruments supplier's stock after selling 20,944 shares during the quarter. Baird Financial Group Inc. owned approximately 0.10% of Glaukos worth $8,185,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of GKOS. Algert Global LLC grew its holdings in Glaukos by 41.9% in the fourth quarter. Algert Global LLC now owns 18,821 shares of the medical instruments supplier's stock worth $2,822,000 after purchasing an additional 5,561 shares during the period. Comerica Bank boosted its holdings in shares of Glaukos by 664.5% in the 4th quarter. Comerica Bank now owns 151,538 shares of the medical instruments supplier's stock worth $22,722,000 after purchasing an additional 131,715 shares during the period. Lido Advisors LLC lifted its holdings in shares of Glaukos by 0.8% in the 4th quarter. Lido Advisors LLC now owns 16,542 shares of the medical instruments supplier's stock worth $2,480,000 after buying an additional 131 shares during the period. Northern Trust Corp lifted its stake in shares of Glaukos by 7.4% during the 4th quarter. Northern Trust Corp now owns 578,673 shares of the medical instruments supplier's stock worth $86,766,000 after purchasing an additional 40,052 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Glaukos in the fourth quarter valued at about $1,903,000. Institutional investors own 99.04% of the company's stock.

Glaukos Price Performance

GKOS traded up $4.61 during trading on Monday, reaching $94.57. The stock had a trading volume of 735,281 shares, compared to its average volume of 682,339. The firm has a market capitalization of $5.40 billion, a price-to-earnings ratio of -32.95 and a beta of 0.83. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 1-year low of $77.10 and a 1-year high of $163.71. The stock has a 50 day moving average of $94.87 and a two-hundred day moving average of $127.31.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. The firm had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm's revenue for the quarter was up 24.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.70) earnings per share. As a group, equities analysts anticipate that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Insider Activity

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at $5,708,568.04. The trade was a 2.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. This trade represents a 4.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.80% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have commented on GKOS. Wells Fargo & Company lowered Glaukos from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $160.00 to $86.00 in a report on Thursday, May 1st. Needham & Company LLC lowered their price objective on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Truist Financial reaffirmed a "buy" rating and set a $135.00 price objective (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Stifel Nicolaus cut their target price on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Finally, Mizuho lowered their target price on Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday, April 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $134.67.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.